Pipeline

PulseSight’s pipeline comprises clinical- and preclinical-stage programs built on over a decade of development, supported by robust preclinical packages and Phase 1/2 clinical studies confirming the potential of PulseSight’s approach1 in terms of activity and safety.

The lead clinical candidate, PST-611, is progressing through clinical development for late-stage dry AMD/GA. The follow-on program, PST-809, has completed preclinical proof-of-concept studies as a potential treatment for wet AMD.

A Clinically Validated Platform with Multiple Applications
List of Programs
PST-611
PST-809
  1. Hoogewoud et al. EYS606 for the Treatment of Non-Infectious Uveitis. Acta Ophthalmologica 99(3): 343 (2019)